Our industry-leading neuroscience portfolio includes FDA-approved treatments for major depressive disorder, agitation associated with dementia due to Alzheimer's disease, excessive daytime sleepiness associated with narcolepsy and obstructive sleep apnea, and migraine, as well as multiple novel product candidates addressing a broad range of serious neurological and psychiatric conditions that impact over 150 million people in the United States. Design and develop fit-for-purpose models, including cost-effectiveness and cost-utility models, cost-consequence analyses, budget impact models, decision trees, cohort and patient-level state-transition models, partitioned-survival models, discrete-event simulations, microsimulations, and disease-progression and natural-history models, as appropriate.